Ganciclovir for Injection, USP is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome, and for the prevention of CMV disease in adult transplant recipients at risk for CMV disease.
According to IQVIA, US sales of Ganciclovir for Injection, USP, 500mg, were approximately $8 million in the 12 months ending April 2021.
Hikma is the third largest US supplier of generic injectable medicines by volume, with a growing portfolio of over 100 products. Today one in every six injectable generic medicines used in US hospitals is a Hikma product.
Focus on Services, Modalities, Applications, Phases, End User, Country Data (11 Countries), and Competitive Landscape - Analysis and ForecastDownload free sample pages
Date: Jun 22, 2021
Share this news: